Novo Nordisk CEO faces US Congress scrutiny over weight-loss drug pricing
U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more...
Novo says Ozempic to be eligible for US price negotiations in less than a year
Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's CEO Lars Fruergaard ...
Novo Nordisk Stock Slips as CEO Faces Senate Inquiry Into Wegovy, Ozempic Prices
Novo Nordisk's (NVO) U.S.-listed shares lost ground Monday, a day before a Senate hearing on the costs of the company's popular weight-loss drugs Wegovy and Ozempic.
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study
Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.
Novo Nordisk faces US congressional grilling over price of weight loss drugs, FT reports
Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the sc...
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The latest news from the Danish drug developer was not encouraging. Its experimental weight loss drug produced results, but also a set of side effects.
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Novo Nordisk's (NVO) U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm's latest obesity treatment showed less effectiveness in higher doses.
Novo's Wegovy Backed by EU Regulator For Obesity-Related Heart Conditions. FDA Could Be Next.
The blockbuster drug strengthens its case that obesity drugs have health benefits beyond weight-loss.
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agon...
EU regulator backs use of Novo's Wegovy for obesity-related heart condition
The European Medicines Agency backed the use of Novo Nordisk's Wegovy in patients with an obesity-related heart condition, the Danish drugmaker said on Thursday.
Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improve...
Wegovy ® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, have multiple positive catalysts, making NVO stock attractive for medium-to-long term investors. Insurance coverage for Ozempic and Wegovy may ...
Novo Nordisk (NVO) Outperforms Broader Market: What You Need to Know
Novo Nordisk (NVO) reachead $136.66 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.
Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy
NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.
Related Companies